Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)

Sponsor
Tulane University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06133322
Collaborator
National Institutes of Health (NIH) (NIH), National Institute on Minority Health and Health Disparities (NIMHD) (NIH)
1,176
1
2
57
20.6

Study Details

Study Description

Brief Summary

The burden of hypertension and related cardiovascular diseases, stroke, and end-stage kidney disease is disproportionately high in Black populations, especially in the South. The Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial aims to test the effectiveness, implementation, and sustainability of a community health worker (CHW)-led multifaceted intervention compared to enhanced usual care for hypertension control in Black communities. In the BLESSED trial, the investigators plan to recruit 1,176 Black adults with hypertension (approximately 28 per church) from 42 churches in the Greater New Orleans area. The multifaceted intervention will last for 18 months, followed by a post-intervention follow-up visit at 24 months. The BLESSED trial aims to generate evidence regarding the effectiveness, implementation, and sustainability of this CHW-led church-based multifaceted intervention in eliminating hypertension disparities in the United States (US) general population.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline
N/A

Detailed Description

Louisiana residents, especially African Americans, bear a disproportionately high burden of hypertension and cardiovascular disease (CVD). In the Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial, the investigators will compare the impact of two implementation strategies - a CHW-led multifaceted strategy and a group-based education strategy - for delivering interventions recommended by the 2017 American College of Cardiology (ACC) and the American Heart Association (AHA) hypertension clinical guidelines on implementation and clinical effectiveness outcomes in Black community members over 18 months. The BLESSED study utilizes an effectiveness-implementation hybrid design to: (1). test the effectiveness of a CHW-led church-based multifaceted implementation strategy for reducing estimated CVD risk over 18 months among African Americans at high risk for CVD, and (2). assess the implementation outcomes (acceptability, adaptation, adoption, feasibility, fidelity, penetrance, cost-effectiveness, and sustainability) simultaneously. The Exploration, Preparation, Implementation, Sustainment (EPIS) framework has guided the development and evaluation of the multifaceted implementation strategy, which includes CHW-led health coaching on lifestyle changes and medication adherence; healthcare delivery in community; church-based exercise and weight loss programs; self-monitoring of blood pressure (BP); and provider education and engagement. The CHW-led church-based intervention will provide strong social support and tackle multiple social determinants of CVD disparities. The primary clinical effectiveness outcome is the difference in mean change of systolic blood pressure (SBP) from baseline to 18 months between intervention and control groups. The primary implementation outcome is a fidelity summary score for key implementation strategy components to the CHW-led church-based multifaceted implementation strategy assessed at the participant levels. This study has 90% statistical power to detect group differences in mean SBP change of 5.8 mm Hg over 18 months using a 2-sided significance level of 0.05. The investigators will recruit 1,176 African American participants (28 per church) who are aged ≥18 years with systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mm Hg, and randomly assign 21 churches to intervention and 21 to control; the investigators will implement the multifaceted intervention program; the investigators will follow-up participants and collect data on effectiveness and implementation outcomes at 6, 12, and 18 months; the investigators will evaluate the sustainability of the intervention at 6 months post-intervention; and the investigators will perform intention-to-treat analyses and disseminate and scale-up the proven-effective implementation strategy. The proposed study will generate evidence on the effectiveness, implementation, and sustainability of the multifaceted intervention aimed at eliminating CVD disparities in African American populations in the US.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1176 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Cluster randomization of 42 churches in New Orleans, Louisiana to 2 armsCluster randomization of 42 churches in New Orleans, Louisiana to 2 arms
Masking:
Single (Outcomes Assessor)
Masking Description:
Clinical research coordinators and laboratory technicians who assess health-related outcomes will be blinded to intervention assignment. Study physicians who review serious adverse events and unanticipated problems will also be blinded to intervention assignment.
Primary Purpose:
Prevention
Official Title:
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2027
Anticipated Study Completion Date :
Aug 1, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Community health worker-led implementation strategy

CHW-led church-based multifaceted implementation strategy: CHWs will conduct individualized health coaching and healthcare navigation, organize church-based health promotion programs (e.g., nutrition education and exercise sessions), and train and assist the study participants in self-monitoring of BP. Nurse practitioners will see study participants at church settings, and community pharmacies will deliver antihypertensive medications to patients' homes.

Behavioral: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline
The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension

Experimental: Group-based Education Strategy

The investigator team will work with church leadership and wellness coordinators to organize group-based education sessions. Health education will be delivered by local primary care providers, dieticians, and health educators. Contact information for primary care providers and information on self-monitoring of BP will also be given at group sessions.

Behavioral: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline
The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension

Outcome Measures

Primary Outcome Measures

  1. Difference in mean change of systolic blood pressure [Measured from baseline to 18 months]

    Difference in mean change of systolic blood pressure from baseline to 18 months between intervention and control groups

  2. Implementation fidelity summary score [Measured at 6, 12, and 18 months]

    The fidelity summary score is composed of the following key implementation strategy components: proportion of assigned health education sessions attended in all participants, proportion of assigned discussion sessions attended in all participants, proportion of recommended minutes of physical activity completed in all participants, proportion of days per week that fruits/vegetables are eaten as recommended in all participants, proportion of recommended home blood pressure (BP) monitoring completed in patients with hypertension, proportion of required provider visits attended in all patients, and proportion of antihypertensive medications taken in patients with hypertension. The score ranged from zero to six with a higher score indicates greater fidelity.

Secondary Outcome Measures

  1. Difference in the proportion of patients with controlled BP between intervention and control groups [Measured from baseline to 18 months]

    Difference in the proportion of patients with controlled BP (<130/80 mm Hg) between intervention and control groups at 18 months

  2. Difference in mean change of diastolic BP [Measured from baseline to 18 months]

    Difference in mean change of diastolic BP (DBP) from baseline to 18 months between intervention and control groups

  3. Side effects of medications and adverse events [Measured from baseline to 18 months]

    Change in side effects of medications and adverse events from baseline to 18 months

  4. Cost-effectiveness [Measured from baseline to 18 months]

    Cost-effectiveness assessed as incremental direct costs per additional percentage of hypertension control

  5. Acceptability [Measured from baseline to 18 months]

    Percentage of participants, community health worker, providers, and church administrators who reply that the intervention is acceptable (satisfactory). Measured by survey.

  6. Adoption (Churches) [Measured from baseline to 18 months]

    % of churches adopting the intervention program

  7. Adoption (Providers) [Measured from baseline to 18 months]

    % of invited providers attending training sessions

  8. Appropriateness [Measured from baseline to 18 months]

    Percentage of participants, community health workers, providers, and church administrators who reply that the intervention is appropriate (good perceived fit). The outcome will be measured by survey question.

  9. Feasibility to participant, community health worker, provider and churches [Measured from baseline to 18 months]

    Percentage of participants, community health worker, providers, and church administrators who reply that the intervention is feasible (actual fit, suitability). Measured by survey and study administrative data.

  10. Exercise Session Fidelity (community health worker-led strategy group) [Measured at 6, 12, and 18 months]

    Percentage of exercise sessions organized. Measured by study administrative data.

  11. Fidelity of Group Health Education Session [Measured at 6, 12, and 18 months]

    Percentage of group health education sessions conducted out of health educated sessions planned per study protocol.

  12. Nutrition Education Session Fidelity (community health worker-led strategy group) [Measured at 6, 12, and 18 months]

    Percentage of nutrition education sessions organized. Measured by study administrative data.

  13. Health Care Appointment Fidelity (community health worker-led strategy group) [Measured at 6, 12, and 18 months]

    Percentage of health care visit appointments made. Measured by study administrative data.

  14. Percentage of enrolled participants receiving assigned intervention. Measured by study administrative data. Reach (Participants) [Measured at baseline, 6, 12, and 18 months]

    Percentage of enrolled participants receiving assigned intervention. Measured by study administrative data.

  15. Reach (Participants) [Measured at baseline]

    The percentage of eligible/screened/contacted participants enrolled. Measured by study data, administrative data.

  16. Penetrance (Participants) [Measured at baseline, 6, 12, and 18 months]

    Percentage of enrolled participants receiving assigned intervention. Measured by intervention monitoring data.

  17. Penetrance (Providers) [Measured at baseline, 6, 12, and 18 months]

    Percentage of trained providers delivering protocol-based care. Measured by intervention monitoring data.

  18. Penetrance (educators) [Measured at baseline, 6, 12, and 18 months]

    Percentage of trained CHWs or providers and health educators delivering health coaching. Measured by intervention monitoring data.

  19. Sustainability (Churches) [Measured at baseline, 6, 12, and 18 months]

    Percentage of churches continuing the intervention program and individual components. Measured by 6-month post-intervention survey.

  20. Sustainability (Participants) [Measured at 24 months]

    Percentage of participants maintaining ideal cardiovascular health metrics, healthy lifestyle components, and adherence to medications. Measured by 6-month post-intervention survey and examination.

  21. Sustainability Effectiveness Outcome: Differences in mean change of SBP and DBP [Measured at baseline and 24 months]

    Differences in mean change of SBP and DBP from baseline to 24 months (6 months post-intervention) between intervention and control groups

  22. Sustainability Effectiveness Outcome: Difference in the proportion of patients with controlled BP [Measured at baseline and 24 months]

    Difference in the proportion of patients with controlled BP (<130/80 mm Hg) between intervention and control groups at 24 months.

  23. Sustainability of Fidelity [Measured at 24 months]

    A fidelity summary score for key implementation strategy components at 6 months post-intervention (24 months overall). The fidelity summary score is composed of the following key implementation strategy components: proportion of assigned health education sessions attended in all participants, proportion of assigned discussion sessions attended in all participants, proportion of recommended minutes of physical activity completed in all participants, proportion of days per week that fruits/vegetables are eaten as recommended in all participants, proportion of recommended home BP monitoring completed in patients with hypertension, proportion of required provider visits attended in all patients, and proportion of antihypertensive medications taken in patients with hypertension. Fidelity score ranges from zero to six with a higher score indicates greater fidelity.

Other Outcome Measures

  1. Change in quality of life [Measured from baseline to 18 months]

    The difference in QoL between the two arms over 18 months. QoL will be assessed using the SF-12 questionnaire. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Black or African American men or women aged ≥18 years

  2. Community members associated with the participating churches (church members and their families and friends)

  3. Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mm Hg

  4. Willing and able to participate in the intervention.

  5. Willing and able to sign written informed consent.

Exclusion Criteria:
  1. Prior hospitalization in the last 3 months for chronic heart failure or heart attack

  2. Current diagnosis of cancer requiring chemotherapy or radiation therapy

  3. Stage-5 chronic kidney disease requiring chronic dialysis or transplant

  4. Pregnant or planning to become pregnant in the next 18 months

  5. Planning to move out of the Greater New Orleans area during the next year

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tulane University New Orleans Louisiana United States 70112

Sponsors and Collaborators

  • Tulane University
  • National Institutes of Health (NIH)
  • National Institute on Minority Health and Health Disparities (NIMHD)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jiang He, MD, PhD, Director Tulane University Translational Science Institute, Tulane University
ClinicalTrials.gov Identifier:
NCT06133322
Other Study ID Numbers:
  • 2022-1081-SPHTM
  • R01MD018193
First Posted:
Nov 15, 2023
Last Update Posted:
Nov 15, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jiang He, MD, PhD, Director Tulane University Translational Science Institute, Tulane University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 15, 2023